Amgen Reports post-marketing Data for Gene therapy in Chronic lymphocytic leukemia

Amgen today announced post-marketing results for gene therapy in patients with chronic lymphocytic leukemia. The study demonstrated that gene therapy reduces biomarker levels compared to standard of care or placebo. These results provide important insights into the treatment of chronic lymphocytic leukemia and support the continued development of gene therapy in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.